Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: health insurance

Charting a New Course Post-PHE

From the College  |  May 23, 2023

The public health emergency (PHE), in place since 2020, officially expired at midnight on May 11. The PHE declaration allowed significant flexibility in the healthcare system. The end of the PHE impacts several policies, including changes in Medicare and Medicaid policies. What do these changes mean for providers?

Filed under:Practice Support Tagged with:COVID-19telehealthU.S. public health emergency

Adobe Stock / ART STOCK CREATIVE

Large Language Models in Medicine: The potential to reduce workloads, leverage the EMR for better communication & more

Jacqueline Jansz, MD, & Peter T. Sadelski, JD  |  May 17, 2023

Large language models are a type of AI that allows users to generate new content, drawing from a huge dataset to learn how to mimic “natural language” with many possible beneficial applications for this technology in medicine.

Filed under:AppsHome SliderPractice SupportTechnology Tagged with:AIartificial intelligencelarge language model

JAK Inhibitors vs. TNF Inhibitors: Understanding Infection Risks

Michele B. Kaufman, PharmD, BCGP  |  April 27, 2023

Research from Choi et al. provides insights into the risk of infection in patients with rheumatoid arthritis (RA), comparing patients treated with Janus kinase inhibitors vs. tumor necrosis inhibitors. The most frequent infection was herpes zoster, with patients treated with JAK inhibitors having a significantly greater risk of herpes zoster infection than those treated with TNF inhibitors.

Filed under:ACR ConvergenceDrug UpdatesMeeting Reports Tagged with:ACR Convergence 2022InfectionJAK inhibitorsJanus Kinase InhibitorsRheumatoid Arthritis (RA)TNF inhibitorstumor necrosis factor (TNF) inhibitors

The Only Rheumatologist on the Island

Samantha C. Shapiro, MD  |  April 8, 2023

“What are you up to this weekend?” “Flying to Guam.” “What? Why?” “I promised an entire island I’d be their doctor.” In fall 2021, Jonathon Thorp, MD, phoned a friend. A passionate internist, he was bound and determined to bring a rheumatologist to Guam. Unlike most primary care providers (PCPs), he was willing to prescribe…

Filed under:Career DevelopmentProfessional Topics Tagged with:Volunteer

Mark Cuban: Mixing Up the Pharmaceutical Landscape

Catherine Kolonko  |  April 7, 2023

The Mark Cuban Cost Plus Drug Co. (CPD) launched in January 2022 to distribute and home deliver prescribed generic medications to consumers. The Texas-based business seeks to reduce the prices of generic drugs by leapfrogging financial negotiators and going straight to drug companies for supply, according to a news release.1 “It’s crazy that medications are…

Filed under:Drug Updates Tagged with:pharmacy benefit managersprescription drug prices

Zoledronic Acid vs. Oral Bisphosphonates: Osteoporosis Treatments & the Risk of Developing Osteonecrosis of the Jaw

Michele B. Kaufman, PharmD, BCGP  |  December 12, 2022

A study from Amigues et al. found that bisphosphonate-associated osteonecrosis of the jaw is rare in patients with osteoporosis and may occur more often in patients treated with injectable zoledronic acid than in those treated with the oral bisphosphonates.

Filed under:ConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:bisphosphonatesEULARONJosteonecrosis of the jawOsteoporosiszoledronic acid

Speak Out Rheum: To Prescribe Is Humane (Unless You’re In Texas)

Raymond Scalettar, MD, DSc  |  November 7, 2022

You are a rheumatologist in Texas. You are very well trained. Your mentors included some of the leaders in rheumatology, and you are respected by your colleagues and your patients. You know the devastation of untreated rheumatoid arthritis and lupus. A young woman with recent onset of systemic lupus erythematosus is your new patient. You…

Filed under:EthicsLegal UpdatesOpinionProfessional TopicsSpeak Out Rheum Tagged with:abortionMethotrexatepregnancySpeak Out Rheumatology

ACR Proposes New ICD-10 Code to Capture ‘Pre-RA’

From the College  |  October 7, 2022

On Sept. 13, the ACR and Kevin D. Deane, MD, PhD, presented a proposal to create a new clinical code to recognize a condition in which an individual may exhibit rheumatoid arthritis-related autoantibodies without clinical presentation.

Filed under:Billing/CodingFrom the College Tagged with:CodingICD-10 code change requestpre-rheumatoid arthritisRheumatoid Arthritis (RA)

2022 RDAM Report Card

Rheumatic Disease Report Card 2022 Released: No A’s Given Overall; Oklahoma Ranks Most Improved

Vanessa Caceres  |  September 13, 2022

The 2022 Rheumatic Disease Report Card found that many states can improve access to care, affordability & activity for their residents living with rheumatic diseases.

Filed under:American College of RheumatologyFrom the College Tagged with:RDAMReport CardRheumatic Disease Awareness Month

How the U.S. Will Set Up New Medicare Drug Price Talks

Ahmed Aboulenein  |  September 6, 2022

WASHINGTON—The U.S. government will soon begin hiring experts and collecting the data needed to launch direct negotiations over prescription drug prices for older and disabled people, a top Biden administration official told Reuters. President Joe Biden last week signed into law the Inflation Reduction Act, introducing new policies to tackle climate change, taxes and the…

Filed under:Drug UpdatesLegislation & Advocacy Tagged with:Centers for Medicare & Medicaid Services (CMS)drug pricingInflation Reduction ActpolicyU.S. Centers for Medicare and Medicaid Services (CMS)

  • « Previous Page
  • 1
  • …
  • 23
  • 24
  • 25
  • 26
  • 27
  • …
  • 117
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences